Skip to content

XBIState Street SPDR S&P Biotech ETF

Grow my money20y track recordRanked #153 of 2,993 in this goal

Tracks the total return performance of the S&P Biotechnology Select Industry Index.

By State Street Investment Management · Launched 2006

Annual Cost

0.35%

#1,645 of 5,853 · low cost

Fund Size

$10.7B

#265 of 5,853 · large

Return (1Y)Goal

+71.2%

Track Record

20 years

#260 of 5,853 · established

Performance

Total-return NAV · USD
Growth of $10,000
$15,100+51.0%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Cap

Multi cap

Strategy

Index tracking

Focus

Biotech & Genomics

Index tracked

S&P Biotechnology Select Industry Index

What it actually holds

By weight

Concentration

Top 10 holdings = 20.4% of fundwell diversified

State Street Global Advisors
8.0%
Apellis Pharmaceuticals Inc
1.8%
Alkermes PLC
1.5%
Madrigal Pharmaceuticals Inc
1.4%
TG Therapeutics Inc
1.3%
Insmed Inc
1.3%
Scholar Rock Holding Corp
1.3%
Apogee Therapeutics Inc
1.3%
Protagonist Therapeutics Inc
1.2%
Summit Therapeutics Inc
1.2%

Asset allocation

Stocks
100.0%
Cash
0.0%

By sector

Healthcare
99.5%
Financial Services
0.5%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
27.0%High

Year-on-year price swings

Max drawdown
-63.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)
0.70Decent risk-adjusted returns
Sortino (3Y)
1.03Good downside protection

Listing

Exchange
NYSE Arca

Full fund details

Objective
Tracks the total return performance of the S&P Biotechnology Select Industry Index.
Strategy
Invests primarily in U.S. biotechnology companies with float-adjusted market capitalizations of at least $500 million, using a sampling strategy to track the S&P Biotechnology Select Industry Index. The Fund may also invest in cash and cash equivalents for management purposes.
Inception date
January 31, 2006
Fund family
State Street Investment Management

What's next?

You've looked at XBI. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

Data updated on 2026-08-02